JP2023542286A5 - - Google Patents

Info

Publication number
JP2023542286A5
JP2023542286A5 JP2023515576A JP2023515576A JP2023542286A5 JP 2023542286 A5 JP2023542286 A5 JP 2023542286A5 JP 2023515576 A JP2023515576 A JP 2023515576A JP 2023515576 A JP2023515576 A JP 2023515576A JP 2023542286 A5 JP2023542286 A5 JP 2023542286A5
Authority
JP
Japan
Prior art keywords
cancer
compound
impairment
tumor
haloethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542286A (ja
Filing date
Publication date
Priority claimed from PCT/CN2020/114519 external-priority patent/WO2021120717A1/zh
Application filed filed Critical
Publication of JP2023542286A publication Critical patent/JP2023542286A/ja
Publication of JP2023542286A5 publication Critical patent/JP2023542286A5/ja
Pending legal-status Critical Current

Links

JP2023515576A 2019-12-20 2021-06-23 低酸素活性化ｄｎａアルキル化剤およびその医学的使用 Pending JP2023542286A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911324466 2019-12-20
PCT/CN2020/114519 WO2021120717A1 (zh) 2019-12-20 2020-09-10 抗癌化合物及其医药用途
CNPCT/CN2020/114519 2020-09-10
PCT/CN2021/101870 WO2022052564A1 (zh) 2019-12-20 2021-06-23 乏氧活化的dna烷化剂及其医药用途

Publications (2)

Publication Number Publication Date
JP2023542286A JP2023542286A (ja) 2023-10-06
JP2023542286A5 true JP2023542286A5 (cg-RX-API-DMAC7.html) 2023-11-02

Family

ID=76477075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515576A Pending JP2023542286A (ja) 2019-12-20 2021-06-23 低酸素活性化ｄｎａアルキル化剤およびその医学的使用

Country Status (7)

Country Link
US (2) US20230026163A1 (cg-RX-API-DMAC7.html)
EP (2) EP4079738A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542286A (cg-RX-API-DMAC7.html)
KR (1) KR20230065309A (cg-RX-API-DMAC7.html)
CN (2) CN114466853B (cg-RX-API-DMAC7.html)
TW (4) TWI837402B (cg-RX-API-DMAC7.html)
WO (2) WO2021120717A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
EP4428138A4 (en) * 2021-11-05 2025-08-27 Ascentawits Pharmaceuticals Ltd AKR1C3-ACTIVATED DNA ALKYLATING AGENT AND ITS MEDICAL USE
CN116120365A (zh) 2021-11-12 2023-05-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN115626938B (zh) * 2022-09-02 2026-04-17 温州医科大学 一种化合物rx4及其在抗结肠癌药物中的作用
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
CN121175032A (zh) * 2023-05-11 2025-12-19 深圳艾欣达伟医药科技有限公司 一种注射液制剂、配伍药液及其制备方法
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617398A (en) * 1982-04-12 1986-10-14 The Research Foundation Of State University Of New York Phosphoaziridine compounds useful for treatment of tumors
AU5935600A (en) * 1999-07-14 2001-01-30 Richard F. Borch Phosphoramide compounds
WO2004062596A2 (en) * 2003-01-09 2004-07-29 Zeneus Pharma Limited Antineoplastic ether lipid compounds having a four carbon backbone
CA2592116A1 (en) * 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2592118C (en) * 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
CN1948311A (zh) * 2006-11-09 2007-04-18 上海交通大学 2－碘代苯基－6－三氟甲基咪唑并[1,2－a]吡啶－3－乙酰胺类化合物及制备方法
US9278904B2 (en) * 2013-12-31 2016-03-08 Chemapotheca, Llc Synthesis of chiral amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds
CN104098432B (zh) * 2014-06-30 2016-03-30 福建师范大学福清分校 一种三氟甲基化芳烃的合成方法
WO2016145092A1 (en) * 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
US20180169064A1 (en) * 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
KR101985778B1 (ko) * 2015-11-16 2019-06-04 아센타위츠 파마슈티컬즈 리미티드 (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조
CN106279321A (zh) 2016-08-09 2017-01-04 南京医科大学 吉西他滨ProTide乏氧活化前药及其应用
CN107118231B (zh) * 2017-03-17 2019-06-07 北京大学 萘醌磷酰胺类化合物及其在作为细胞铁死亡诱导剂中的用途
WO2018184003A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Modulating dsrna editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
CN107513057A (zh) 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
WO2020022868A1 (ko) * 2018-07-27 2020-01-30 에스케이이노베이션 주식회사 입자 균일도가 우수한 모데나이트 제올라이트 및 그 제조방법
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Similar Documents

Publication Publication Date Title
Zhu et al. Modern approaches for asymmetric construction of carbon− fluorine quaternary stereogenic centers: synthetic challenges and pharmaceutical needs
US8440677B2 (en) Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
Xie et al. Asymmetric synthesis of quaternary α-fluoro-β-keto-amines via detrifluoroacetylative Mannich reactions
Huang et al. Highly enantioselective zinc/BINOL-catalyzed alkynylation of α-ketoimine ester: a new entry to optically active quaternary α-CF3 α-amino acids
TW202014400A (zh) 多環型胺甲醯基吡啶酮化合物之合成
Corey et al. Kinetic resolution by enantioselective dihydroxylation of secondary allylic 4-methoxybenzoate esters using a mechanistically designed cinchona alkaloid catalyst
EP3848371A1 (en) Tricyclic furan-substituted piperidinedione compound
JP2024539385A5 (cg-RX-API-DMAC7.html)
EP3641776B1 (en) Atropisomerism for enhanced kinase inhibitor selectivity
US10081620B2 (en) Radioactive fluorine labeling precursor compound and method for manufacturing radioactive fluorine labeled compound using the same
US9206090B2 (en) Tricyclic chiral compounds and their use in asymmetric catalysis
EP4353715A1 (en) 6-substituted chirally pure difluoropiperidine quinazoline derivative and preparation method therefor
Kim et al. Stereoselective synthesis of 4-substituted-cyclic sulfamidate-5-carboxylates by asymmetric transfer hydrogenation accompanied by dynamic kinetic resolution and applications to concise stereoselective syntheses of (−)-epi-cytoxazone and the taxotere side-chain
EP4071146A1 (en) Biaryl compound as pan-raf kinase inhibitor
Guo et al. Practical Asymmetric Synthesis of a Bicyclic Pyrrolidinol
Xu et al. Efficient manufacturing process for the selective estrogen receptor degrader GDC-9545 (Giredestrant) via a crystallization-driven diastereoselective Pictet–Spengler condensation
Dowling et al. Two scalable syntheses of (S)-2-methylazetidine
CN102516152A (zh) 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用
KR101879143B1 (ko) 2-아미노 치환 벤즈알데히드 화합물을 제조하는 방법
WO2014109256A1 (ja) トリアゾール連結型環状ジヌクレオチド類縁体
Turockin et al. Synthesis of chiral bicyclic guanidinium salts using di (imidazole-1-yl) methanimine
CN114591333B (zh) 一种吡咯并嘧啶类化合物的制备方法
Pešić et al. Synthesis and Electrochemical Estimation of DNA-Binding Capacity of Novel Ferrocene-Containing Pyrrolidines
CN117886850B (zh) 一种叠氮化合物的制备方法
Sharma et al. Ligand-free Pd-catalyzed double Heck reaction of N-(o-bromoaryl) acrylamides with α-F/CF3-acrylates